The most important peptide-related publication of the week landed in The Lancet. The SEMALCO trial—a randomized, double-blind, placebo-controlled study of once-weekly semaglutide in adults with alcohol use disorder and comorbid obesity—reports that 26 weeks of semaglutide reduced heavy drinking days by 13.7 percentage points more than placebo, with an estimated number-needed-to-treat (NNT) of 4.3 to produce a clinically meaningful response. (The Lancet00305-3/fulltext))

That NNT, if it holds in larger trials, is better than what naltrexone, acamprosate, or disulfiram—the three FDA-approved medications for alcohol use disorder—achieve in their head-to-head and placebo-controlled trial portfolios. Combined with semaglutide’s established profile in obesity, type 2 diabetes, and cardiovascular outcomes, this is the strongest evidence yet that the GLP-1 receptor agonist class is therapeutically relevant well beyond metabolic disease.

What SEMALCO Tested

SEMALCO enrolled 108 treatment-seeking adults with alcohol use disorder and comorbid obesity at the Mental Health Centre Copenhagen in Denmark. Patients were randomized to receive once-weekly subcutaneous semaglutide titrated to 2.4 mg, or matching placebo (saline subcutaneous), for 26 weeks. Both arms received standard cognitive behavioral therapy as the underlying intervention.

The primary endpoint was reduction in the number of heavy drinking days during the past 30 days at the 26-week mark. Heavy drinking was defined per WHO conventions: more than 48 grams of alcohol per day for women, more than 60 grams per day for men—approximately three to four standard drinks. Secondary endpoints included total alcohol consumption, AUDIT scores, and alcohol biomarkers.

What the Trial Found

Across the trial, semaglutide produced an estimated treatment difference of 13.7 percentage points in heavy drinking days reduction versus placebo (95% CI −22.0 to −5.4). Total alcohol consumption fell from approximately 2,200 grams per 30 days at baseline to approximately 650 grams per 30 days in the semaglutide arm, versus a fall to approximately 1,175 grams per 30 days in the placebo arm. AUDIT scores and alcohol biomarkers improved on the same direction. Alcohol craving and drinks per drinking day both decreased.

The implied NNT, calculated from the response-rate data, is 4.3. For comparison, the FDA-approved AUD medications—naltrexone, acamprosate, and disulfiram—generally produce NNTs of 7 to 10 in their best evidence. The SEMALCO finding, if confirmed in a larger trial, would represent the strongest pharmacological signal in AUD treatment in roughly two decades.

Adverse events in the semaglutide arm were consistent with the known semaglutide safety profile: transient gastrointestinal effects (nausea, mild GI distress), most resolving with continued treatment. No new safety signals emerged.

What the Trial Doesn’t Tell Us

Three honest limitations.

The trial enrolled patients with AUD and obesity. The mechanism by which semaglutide reduces heavy drinking is not fully characterized—it could be related to GLP-1’s central effects on reward pathways, to weight loss-mediated effects on alcohol metabolism, or to a combination. Whether the effect generalizes to AUD patients without obesity is not directly answerable from this trial. The next-stage trials, if they’re funded, will need to enroll AUD-only populations.

Single-center, single-country, Danish patient population. SEMALCO was conducted entirely at the Mental Health Centre Copenhagen. Replication in U.S. populations, with different patterns of alcohol consumption, comorbid mental health conditions, and demographic profiles, is the necessary next step. The Hendershot et al. trial in JAMA Psychiatry in 2025 (PMID 39937469) showed similar directional signals in a smaller U.S. study, which strengthens the SEMALCO finding but does not replicate it at scale.

Twenty-six weeks. AUD treatment is a long-term proposition. The 26-week duration of SEMALCO is a meaningful efficacy window but does not address whether the reduction in heavy drinking is sustained at one year, two years, or beyond. AUD relapse rates after pharmacological treatment cessation are high; whether semaglutide produces durable reductions or whether the effect is contingent on continued treatment is not established by this trial.

Why This Matters Beyond AUD

The SEMALCO finding contributes to an accumulating evidence base that the GLP-1 class affects central reward circuitry in ways that are clinically relevant for several behavioral and psychiatric indications. Recent research has reported potential signals in nicotine dependence, opioid use disorder, gambling disorder, compulsive eating, and several neurodegenerative diseases. NeurologyLive has been covering the broader GLP-1 neurology repositioning in detail.

The mechanism—GLP-1 receptor activation modulating dopaminergic signaling in the mesolimbic reward pathway—is biologically plausible and is consistent with what the Stanford PAM and 23andMe Nature pharmacogenomics studies are also revealing about GLP-1 biology being more nuanced than the obesity-focused framing has captured. The drugs are not just appetite suppressants. They are central nervous system-active compounds with effects across reward, metabolism, and inflammation that are still being characterized.

For the full evidence picture on semaglutide—including cardiovascular outcomes, kidney outcomes, neurodegeneration data, and the emerging AUD signal—our semaglutide compound article walks through the complete evidence portfolio.

What’s Likely Next

Three things to watch.

A larger, multicenter SEMALCO-style trial in AUD patients without obesity is the necessary follow-up to convert this signal into regulatory-grade evidence. If Novo Nordisk or an academic consortium funds it—and the Lancet publication is the kind of result that typically catalyzes that funding—Phase 3-scale data could be in hand within 18 to 24 months.

Off-label use will likely accelerate. Some clinicians treating AUD will read this paper and consider semaglutide for patients who have not responded to first-line treatments and for whom the side effect profile is acceptable. That is a clinical judgment that should rest with the prescriber and patient. It is not, and does not become through this trial, a labeled indication.

The mainstream media response will be substantial. ABC News, NIH News, and Science Media Centre have already covered the publication, and consumer-facing search interest in “Ozempic for alcohol” is likely to spike over the next two weeks. The trial’s findings are real, the framing in much of that coverage will inevitably overshoot the trial’s evidence base. Peptidings’ role is to keep the framing precise: a 108-patient single-center trial with a striking effect size, a strong replication context from an earlier U.S. study, and a path to larger trials that will determine whether this signal becomes a treatment.

References

1. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. The Lancet. May 2026. DOI: S0140-6736(26)00305-3. The Lancet00305-3/fulltext)
2. Adding weekly GLP-1 to cognitive behavioral therapy further reduces heavy drinking. NIH News Release. May 2026. NIH
3. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial (Hendershot et al.). JAMA Psychiatry. 2025. PMID 39937469. JAMA Network
4. Expert reaction to an RCT for semaglutide in patients with alcohol use disorder and comorbid obesity. Science Media Centre. 2026. Science Media Centre
5. ClinicalTrials.gov. NCT05520775 — Semaglutide for Alcohol Use Disorder. ClinicalTrials.gov